Compare BANR & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BANR | MLYS |
|---|---|---|
| Founded | 1890 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 1.9B |
| IPO Year | 2015 | 2023 |
| Metric | BANR | MLYS |
|---|---|---|
| Price | $61.84 | $26.93 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 6 |
| Target Price | ★ $71.20 | $48.67 |
| AVG Volume (30 Days) | 280.1K | ★ 1.2M |
| Earning Date | 04-22-2026 | 03-12-2026 |
| Dividend Yield | ★ 3.30% | N/A |
| EPS Growth | 15.57 | ★ 37.43 |
| EPS | ★ 5.64 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $0.73 | N/A |
| Revenue Next Year | $5.69 | N/A |
| P/E Ratio | $10.76 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $54.01 | $10.44 |
| 52 Week High | $69.83 | $47.65 |
| Indicator | BANR | MLYS |
|---|---|---|
| Relative Strength Index (RSI) | 59.64 | 53.43 |
| Support Level | $61.73 | $26.85 |
| Resistance Level | $65.31 | $31.09 |
| Average True Range (ATR) | 1.25 | 1.59 |
| MACD | 0.42 | 0.41 |
| Stochastic Oscillator | 99.33 | 68.09 |
Banner Corp is a bank holding company. It wholly owns one subsidiary bank, Banner Bank. The Bank's primary business is that of traditional banking institutions, accepting deposits and originating loans in locations surrounding its offices in Washington, Oregon, California, Idaho and Utah. Banner Bank also actively participates in the secondary loan markets, engaging in mortgage banking operations largely through the origination and sale of one to four family residential loans.
Mineralys Therapeutics Inc is a biopharmaceutical company focused on developing medicines to target diseases driven by dysregulated aldosterone. The Company's product candidate, lorundrostat, is a proprietary, orally administered, aldosterone synthase inhibitor that the Company is developing for the treatment of cardiorenal conditions affected by dysregulated aldosterone, including hypertension and related comorbidities, such as chronic kidney disease and obstructive sleep apnea. Its product candidate, lorundrostat, is a proprietary, orally administered, selective ASI that is designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for producing the hormone.